Cheryl L. Maslen

Prof. Cheryl L. Maslen

Knight Cardiovascular Institute, Oregon Health & Science University, CH14M, 3181 SW Sam Jackson Park Rd, Portland OR 97239, USA
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2003 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SRSusan W. Robinson
Susan W. Robinson
CMCynthia D. Morris
Cynthia D. Morris
EGElizabeth Goldmuntz
Elizabeth Goldmuntz
MRMark D. Reller
Mark D. Reller
MJMelanie A. Jones
Melanie A. Jones
CMCheryl L. Maslen
Cheryl L. Maslen

1 January 2012 in Acta Biomaterialia
Verified
Journal Article
Closed access
KMKathryn A. McKenna
Kathryn A. McKenna
MHMonica T. Hinds
Monica T. Hinds
RSRebecca C. Sarao
Rebecca C. Sarao
PWPing-Cheng Wu
Ping-Cheng Wu
CMCheryl L. Maslen
Cheryl L. Maslen
KGKenton W. Gregory
Kenton W. Gregory

1 October 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CAChristine Ackerman
Christine Ackerman
ALAdam E. Locke
Adam E. Locke
EFEleanor Feingold
Eleanor Feingold
BRBenjamin Reshey
Benjamin Reshey
KEKarina Espana
Karina Espana
CMCheryl L. Maslen
Cheryl L. Maslen

3 October 2018 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
HCHolly Corbitt
Holly Corbitt
SMShaine Alaine Morris
Shaine Alaine Morris
CGClaus H. Gravholt
Claus H. Gravholt
KMKristian H. Mortensen
Kristian H. Mortensen
RTRebecca Tippner-Hedges
Rebecca Tippner-Hedges
GIGenTAC Registry Investigators
GenTAC Registry Investigators
Turner syndrome is caused by complete or partial loss of the second sex chromosome, occurring in ~1 in 2,000 female births. There is a greatly increased incidence of aortopathy of unknown etiology, including bicuspid aortic valve (BAV), thoracic aortic aneurysms, aortic dissection and rupture. We performed whole exome sequencing on 188 Turner syndrome participants from the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Related Conditions (GenTAC). A gene-based burden test, the optimal sequence kernel association test (SKAT-O), was used to evaluate the data with BAV and aortic dimension z-scores as covariates. Genes on chromosome Xp were analyzed for the potential to contribute to aortopathy when hemizygous. Exome analysis revealed that TIMP3 was associated with indices of aortopathy at exome-wide significance (p = 2.27 x 10−7), which was replicated in a separate cohort. The analysis of Xp genes revealed that TIMP1, which is a functionally redundant paralogue of TIMP3, was hemizygous in >50% of our discovery cohort and that having only one copy of TIMP1 increased the odds of having aortopathy (OR = 9.76, 95% CI = 1.91–178.80, p = 0.029). The combinatorial effect of a single copy of TIMP1 and TIMP3 risk alleles further increased the risk for aortopathy (OR = 12.86, 95% CI = 2.57–99.39, p = 0.004). The products of genes encoding tissue inhibitors of matrix metalloproteinases (TIMPs) are involved in development of the aortic valve and protect tissue integrity of the aorta. We propose that the combination of X chromosome TIMP1 hemizygosity and variants of its autosomal paralogue TIMP3, significantly increases the risk of aortopathy in Turner syndrome. BAV is the most frequent congenital heart defect, occurring in about 1–2% of the population with 70% of cases occurring in males. BAV increases risk for thoracic aortic aneurysm (TAA) and early death. Approximately 30% of individuals with Turner syndrome have BAV/TAA, making this an important population for the study of this disease. Given that individuals with Turner syndrome are missing a complete or partial second sex chromosome, it is presumed that X chromosome genes are involved in causing the defect. This is consistent with the bias towards occurrence in euploid males. However, not everyone with Turner syndrome has a BAV, so we hypothesized that autosomal genes may also play a role. Using whole exome sequencing we have shown that deleterious variation in TIMP3 is associated with BAV and indices of TAA. We further found that there is a synergistic interaction between loss of the X chromosome gene, TIMP1, and deleterious variation in TIMP3 that significantly increases that risk. TIMP1 and TIMP3 play roles in aortic valve morphogenesis and in stabilizing the aortic wall, loss of which leads to TAA. Hence our findings have implications for understanding the cause of BAV/TAA in all populations and as a potential therapeutic target.

26 October 2006 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
CMCheryl L. Maslen
Cheryl L. Maslen
DBDarcie Babcock
Darcie Babcock
SRSusan W. Robinson
Susan W. Robinson
LBLora J. H. Bean
Lora J. H. Bean
KDKenneth J. Dooley
Kenneth J. Dooley
SSStephanie L. Sherman
Stephanie L. Sherman

14 June 2018 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
CMCheryl L. Maslen
Cheryl L. Maslen
Congenital heart defects (CHD) occur in ∼1 in every 100 live births. In addition, an estimated 10% of fetal loss is due to severe forms of CHD. This makes heart defects the most frequently occurring birth defect and single cause of in utero fatality in humans. There is considerable evidence that CHD is heritable, indicating a strong contribution from genetic risk factors. There are also known external environmental exposures that are significantly associated with risk for CHD. Hence, the majority of CHD cases have long been considered to be multifactorial, or generally caused by the confluence of several risk factors potentially from genetic, epigenetic, and environmental sources. Consequently, a specific cause can be very difficult to ascertain, although patterns of associations are very important to prevention. While highly protective of the fetus, the in utero environment is not immune to insult. As the conduit between the mother and fetus, the placenta plays an essential role in maintaining fetal health. Since it is not a fully-formed organ at the onset of pregnancy, the development of the placenta must keep pace with the growth of the fetus in order to fulfill its critical role during pregnancy. In fact, the placenta and the fetal heart actually develop in parallel, a phenomenon known as the placenta–heart axis. This leaves the developing heart particularly vulnerable to early placental insufficiency. Both organs share several developmental pathways, so they also share a common vulnerability to genetic defects. In this article we explore the coordinated development of the placenta and fetal heart and the implications for placental involvement in the etiology and pathogenesis of CHD.